Drug Discovery for Protozoan Parasites
joint with Fungal Pathogens: From Basic Biology to Drug Discovery
Organizer(s): Norman C. Waters, Frederick S. Buckner and Vicky M. AveryDate: January 15 - 20, 2012
Location: Santa Fe Community Convention Center, Santa Fe, NM, USA
Hundreds of millions of people world-wide are infected each year with protozoan parasites. The mortality and morbidity associated with these diseases are expected to increase due to the development of drug resistant parasites, the absence of adequate vaccines and a shortage of anti-protozoan agents in the drug development pipelines. Understanding the pathogenesis, mechanisms of growth and differentiation, and metabolic processes of the parasites has provided new insights and challenges in the identification of novel drug targets for malaria, leishmaniasis and trypanosomiasis. Integrated strategies combining target identification and validation with advances in structural biology, genetic manipulations and high-throughput high-content screening platforms are likely to accelerate the development of anti-protozoan drugs. This conference is the only international meeting that addresses the development of drugs to treat and prevent parasite infections. Parasitologists, chemists, pharmacologists and clinicians from academia, government and industry will come together to discuss opportunities for the advancement of novel anti-protozoan chemotypes and progression of lead compounds into clinical development. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Fungal Pathogens: From Basic Biology to Drug Discovery, which will share a keynote address and two plenary sessions with this meeting.
Global Health Travel Award Deadline: August 16 2011
Scholarship Deadline: September 19 2011
Discounted Abstract Deadline: September 19 2011
Abstract Deadline: October 19 2011
Discounted Registration Deadline: November 15 2011
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Anacor Pharmaceuticals, Inc.
Genomics Institute of the Novartis Research Foundation
Novartis Institute for Tropical Diseases
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI098157-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.